Abstract: A heat exchanger includes an outer tube having a first axial end and a second axial end, and a pressure barrier tube positioned generally concentric to and within the outer tube such that a first flowpath is defined axially through at least a portion of the outer tube and radially between the outer tube and the pressure barrier tube. A second flowpath is defined within and at least partially axially through the pressure barrier tube. The heat exchanger also includes a first plurality of fins coupled to and extending between the outer tube and the pressure barrier tube, through the first flowpath, and a second plurality of fins coupled to and extending radially inward from the pressure barrier tube, through the second flowpath. A first fluid in the first flowpath exchanges heat with a second fluid in the second flowpath via heat transfer through the first plurality of fins, the pressure barrier tube, and the second plurality of fins.

Abstract: A heat exchanger includes an outer tube having a first axial end and a second axial end, and a pressure barrier tube positioned generally concentric to and within the outer tube such that a first flowpath is defined axially through at least a portion of the outer tube and radially between the outer tube and the pressure barrier tube. A second flowpath is defined within and at least partially axially through the pressure barrier tube. The heat exchanger also includes a first plurality of fins coupled to and extending between the outer tube and the pressure barrier tube, through the first flowpath, and a second plurality of fins coupled to and extending radially inward from the pressure barrier tube, through the second flowpath. A first fluid in the first flowpath exchanges heat with a second fluid in the second flowpath via heat transfer through the first plurality of fins, the pressure barrier tube, and the second plurality of fins.

Abstract: The present invention comprises a VPAC-2 receptor agonist of the formula (I): or a pharmaceutically acceptable salt thereof. Underlined residues indicate a side-chain to side-chain covalent linkage of the first and last amino acids within the segment. The present invention also encompasses pharmaceutical compositions containing such agonists, and the use of such agonists for the treatment of pulmonary diseases including COPD.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Abstract: Provided herein are compounds of the formula (1): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Abstract: Compounds of formula (I) are provided, wherein R1 and R2 are as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.